Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4782MR)

This product GTTS-WQ4782MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4782MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2560MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ4341MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ5210MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ9779MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ4045MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ1907MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ8391MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ4981MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW